Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy.
about
Effects of anti-tumor necrosis factor α agents on bonePrevention and treatment of bone changes associated with exposure to glucocorticoidsWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?The Systemic Effect of Burn Injury and Trauma on Muscle and Bone Mass and Composition.Bone remodelling markers in rheumatoid arthritis.Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritisOsteoblast Role in Rheumatic Diseases.Association of microstructural and mechanical properties of cancellous bone and their fracture risk assessment tool scoresManagement and evaluation of extra-articular manifestations in spondyloarthritisInitiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesEffects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.Osteoporosis and osteoarthritis, rheumatoid arthritis and spondylarthropathies.Pharmacogenomics of biological treatment in rheumatoid arthritis.Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis.Phytoestrogens directly inhibit TNF-α-induced bone resorption in RAW264.7 cells by suppressing c-fos-induced NFATc1 expression.Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis.A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis.Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFα therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabThe P2X7 receptor: a key player in immune-mediated bone loss?Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study
P2860
Q26851274-477CBD08-DDC8-4300-9E94-34A60BC84E9FQ26861474-28C5EC9E-1766-4047-A431-793A92526754Q28074148-1503195C-939A-4028-9EEC-472D1FBD0BE1Q30760745-39E15FA9-1452-42DE-958F-84C920033795Q33563068-B5EE9BE4-3A8F-4FE6-8F4A-2C49E531AF0AQ33648507-6760C65B-D0F3-40B5-977F-2DE307574800Q33838967-0EA10D12-5D12-4670-8169-5785067FBBCFQ35643817-E73B8097-1071-4BF0-85AA-2D3F945E66EBQ36439889-BA31E045-BA28-4A27-82E9-97ECA028EC77Q36781280-48E52867-B14F-4A09-9691-4D366A9110C1Q37051820-396441CF-175E-4795-8C9D-57B68AD9ED39Q38148506-0BEC50EF-D93F-4916-9D61-2ED0EE1EA226Q38167894-CB6FD3EA-F07C-4591-9241-1E7CA42B8170Q38831392-E65F7D2A-B670-4F91-88E5-9183978BB7FEQ39602490-BE0D81E4-9842-44F3-819C-E57ACA3900D8Q40955608-DFDF0426-E657-489D-8F11-60B07C94952EQ45787030-44F599B1-B814-4D14-851E-1DB4040716BDQ45832844-842BE9EC-CFA7-4FFF-B5BE-35D4FE9880B2Q55717414-B75A57EC-67FC-41CE-AE98-A24B84DDDB46Q58799794-41EF9B91-25BF-4752-A56E-3D153402FBB8
P2860
Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@en
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@nl
type
label
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@en
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@nl
prefLabel
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@en
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@nl
P1476
Effect of tumor necrosis facto ...... ritis and spondyloarthropathy.
@en
P2093
David A Hanley
P304
P356
10.1016/J.SEMARTHRIT.2008.04.004
P577
2008-06-30T00:00:00Z